Literature DB >> 22833450

5'-ectonucleotidase mediates multiple-drug resistance in glioblastoma multiforme cells.

Claudia Quezada1, Wallys Garrido, Carlos Oyarzún, Katia Fernández, Rodrigo Segura, Rómulo Melo, Paola Casanello, Luis Sobrevia, Rody San Martín.   

Abstract

Glioblastoma multiforme (GBM) cells are characterised by their extreme chemoresistance. The activity of multiple-drug resistance (MDR) transporters that extrude antitumor drugs from cells plays the most important role in this phenomenon. To date, the mechanism controlling the expression and activity of MDR transporters is poorly understood. Activity of the enzyme ecto-5'-nucleotidase (CD73) in tumor cells, which hydrolyses AMP to adenosine, has been linked to immunosuppression and prometastatic effects in breast cancer and to the proliferation of glioma cells. In this study, we identify a high expression of CD73 in surgically resected samples of human GBM. In primary cultures of GBM, inhibition of CD73 activity or knocking down its expression by siRNA reversed the MDR phenotype and cell viability was decreased up to 60% on exposure to the antitumoral drug vincristine. This GBM chemosensitization was caused by a decrease in the expression and activity of the multiple drug associated protein 1 (Mrp1), the most important transporter conferring multiple drug resistance in these cells. Using pharmacological modulators, we have recognized the adenosine A(3) receptor subtype in mediation of the chemoresistant phenotype in these cells. In conclusion, we have determined that the activity of CD73 to trigger adenosine signaling sustains chemoresistant phenotype in GBM cells.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22833450     DOI: 10.1002/jcp.24168

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  33 in total

1.  Anti-CD73 in cancer immunotherapy: awakening new opportunities.

Authors:  Luca Antonioli; Gennady G Yegutkin; Pál Pacher; Corrado Blandizzi; György Haskó
Journal:  Trends Cancer       Date:  2016-02-01

2.  Nasal Administration of Cationic Nanoemulsions as CD73-siRNA Delivery System for Glioblastoma Treatment: a New Therapeutical Approach.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; I C Iser; G S Lenz; F H de Oliveira; G Venturin; S Greggio; J C daCosta; M R Wink; J Sevigny; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Mol Neurobiol       Date:  2019-08-12       Impact factor: 5.590

Review 3.  Pathological overproduction: the bad side of adenosine.

Authors:  Pier Andrea Borea; Stefania Gessi; Stefania Merighi; Fabrizio Vincenzi; Katia Varani
Journal:  Br J Pharmacol       Date:  2017-03-31       Impact factor: 8.739

4.  NTPDase3 and ecto-5'-nucleotidase/CD73 are differentially expressed during mouse bladder cancer progression.

Authors:  Liliana Rockenbach; Elizandra Braganhol; Fabrícia Dietrich; Fabrício Figueiró; Manoella Pugliese; Maria Isabel Albano Edelweiss; Fernanda Bueno Morrone; Jean Sévigny; Ana Maria Oliveira Battastini
Journal:  Purinergic Signal       Date:  2014-01-26       Impact factor: 3.765

5.  Loss of CD73-mediated actin polymerization promotes endometrial tumor progression.

Authors:  Jessica L Bowser; Michael R Blackburn; Gregory L Shipley; Jose G Molina; Kenneth Dunner; Russell R Broaddus
Journal:  J Clin Invest       Date:  2015-12-07       Impact factor: 14.808

6.  Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas.

Authors:  Shuo Xu; Qian-Qian Shao; Jin-Tang Sun; Ning Yang; Qi Xie; Dong-Hai Wang; Qi-Bing Huang; Bin Huang; Xin-Yu Wang; Xin-Gang Li; Xun Qu
Journal:  Neuro Oncol       Date:  2013-06-04       Impact factor: 12.300

7.  CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.

Authors:  J H Azambuja; R S Schuh; L R Michels; N E Gelsleichter; L R Beckenkamp; G S Lenz; F H de Oliveira; M R Wink; M A Stefani; A M O Battastini; H F Teixeira; E Braganhol
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-16       Impact factor: 3.333

8.  CD73: an emerging checkpoint for cancer immunotherapy.

Authors:  Siqi Chen; Derek A Wainwright; Jennifer D Wu; Yong Wan; Daniela E Matei; Yi Zhang; Bin Zhang
Journal:  Immunotherapy       Date:  2019-06-21       Impact factor: 4.196

9.  Increased Extracellular Adenosine in Radiotherapy-Resistant Breast Cancer Cells Enhances Tumor Progression through A2AR-Akt-β-Catenin Signaling.

Authors:  Hana Jin; Jong-Sil Lee; Dong-Chul Kim; Young-Shin Ko; Gyeong-Won Lee; Hye-Jung Kim
Journal:  Cancers (Basel)       Date:  2021-04-27       Impact factor: 6.639

Review 10.  Targeting CD73 to augment cancer immunotherapy.

Authors:  Meejeon Roh; Derek A Wainwright; Jennifer D Wu; Yong Wan; Bin Zhang
Journal:  Curr Opin Pharmacol       Date:  2020-08-07       Impact factor: 5.547

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.